

Claims 6 and 9, line 1 of each; change "Modification A" to -- The crystal modification --.

Claim 7, line 1; change "Modification" to -- Crystal modification --.

Claims 13 and 14, line 1 of each; change "A modification" to -- Crystal modification A --.

Please add the following new claims:

-- 26. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of crystal modification A of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide according to Claim 1. --

-- 27. A method of treating epilepsy comprising administering to a subject in need of such treatment a therapeutically effective amount of crystal modification A of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide according to Claim 1. --

-- 28. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of crystal modification A' of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide according to Claim 7. --

-- 29. A method of treating epilepsy comprising administering to a subject in need of such treatment a therapeutically effective amount of crystal modification A' of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide according to Claim 7. --

-- 30. The crystal modification A' of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide, characterized in that it is identical to the modification A according to Claim 13 but has defects in the crystal lattice. --

-- 31. The crystal modification A' of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide, characterized in that it is identical to the modification A according to Claim 14 but has defects in the crystal lattice. --